Liquidia Shares Climb to All-Time High Amid Surging Revenue

Dow Jones

05/12

By Christopher Kuo

Liquidia shares rose to an all-time high as the company's product sales drove a surge in first-quarter revenue.

Shares of the biopharmaceutical company focused on cardiopulmonary diseases rose 17% on Monday to $49.56. The stock reached an all-time high of $50.50 on Monday.

The company posted a first-quarter profit of $52.9 million, or 52 cents a share, compared with a profit of $38.4 million, or 45 cents a share, a year earlier. Analysts polled by FactSet expected 41 cents a share.

Revenue climbed to $132.9 million from $3.1 million a year earlier. Analysts expected $119.4 million. The growth was driven by sales of the Yutrepia treatment for pulmonary hypertension. Product sales of Yutrepia were $129.9 million in the quarter, the company said.

The company began shipping Yutrepia to U.S. customers in June, following approval by the Food and Drug Administration on May 23, 2025.

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

May 11, 2026 12:36 ET (16:36 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2634235023"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2634235023\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2634235023?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-12 00:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634235023","market":"nz","top_or_hot":-1,"title":"Liquidia Shares Climb to All-Time High Amid Surging Revenue","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Liquidia shares rose to an all-time high as the company's product sales drove a surge in first-quarter revenue. \n</p>\n<p>\n  Shares of the biopharmaceutical company focused on cardiopulmonary diseases rose 17% on Monday to $49.56. The stock reached an all-time high of $50.50 on Monday. \n</p>\n<p>\n  The company posted a first-quarter profit of $52.9 million, or 52 cents a share, compared with a profit of $38.4 million, or 45 cents a share, a year earlier. Analysts polled by FactSet expected 41 cents a share. \n</p>\n<p>\n  Revenue climbed to $132.9 million from $3.1 million a year earlier. Analysts expected $119.4 million. The growth was driven by sales of the Yutrepia treatment for pulmonary hypertension. Product sales of Yutrepia were $129.9 million in the quarter, the company said. \n</p>\n<p>\n  The company began shipping Yutrepia to U.S. customers in June, following approval by the Food and Drug Administration on May 23, 2025. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 11, 2026 12:36 ET (16:36 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Liquidia Shares Climb to All-Time High Amid Surging Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLiquidia Shares Climb to All-Time High Amid Surging Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-12 00:36</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Liquidia shares rose to an all-time high as the company's product sales drove a surge in first-quarter revenue. \n</p>\n<p>\n  Shares of the biopharmaceutical company focused on cardiopulmonary diseases rose 17% on Monday to $49.56. The stock reached an all-time high of $50.50 on Monday. \n</p>\n<p>\n  The company posted a first-quarter profit of $52.9 million, or 52 cents a share, compared with a profit of $38.4 million, or 45 cents a share, a year earlier. Analysts polled by FactSet expected 41 cents a share. \n</p>\n<p>\n  Revenue climbed to $132.9 million from $3.1 million a year earlier. Analysts expected $119.4 million. The growth was driven by sales of the Yutrepia treatment for pulmonary hypertension. Product sales of Yutrepia were $129.9 million in the quarter, the company said. \n</p>\n<p>\n  The company began shipping Yutrepia to U.S. customers in June, following approval by the Food and Drug Administration on May 23, 2025. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 11, 2026 12:36 ET (16:36 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LQDA","symbol_name":"Liquidia Technologies Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2634235023","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2634235023","pubTimestamp":1778517360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Liquidia shares rose to an all-time high as the company's product sales drove a surge in first-quarter revenue.Shares of the biopharmaceutical company focused on cardiopulmonary diseases rose 17% on Monday to $49.56. The stock reached an all-time high of $50.50 on Monday.The company posted a first-quarter profit of $52.9 million, or 52 cents a share, compared with a profit of $38.4 million, or 45 cents a share, a year earlier. Analysts polled by FactSet expected 41 cents a share.Revenue climbed to $132.9 million from $3.1 million a year earlier. Analysts expected $119.4 million. The growth was driven by sales of the Yutrepia treatment for pulmonary hypertension. Product sales of Yutrepia were $129.9 million in the quarter, the company said.The company began shipping Yutrepia to U.S. customers in June, following approval by the Food and Drug Administration on May 23, 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LQDA":"Liquidia Technologies Inc","BK4007":"制药"},"translate_title":"收入激增，Liquidia股价攀升至历史新高","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LQDA":0.9},"content_text":"By Christopher Kuo \n\n\n \n\n\n  Liquidia shares rose to an all-time high as the company's product sales drove a surge in first-quarter revenue. \n\n\n  Shares of the biopharmaceutical company focused on cardiopulmonary diseases rose 17% on Monday to $49.56. The stock reached an all-time high of $50.50 on Monday. \n\n\n  The company posted a first-quarter profit of $52.9 million, or 52 cents a share, compared with a profit of $38.4 million, or 45 cents a share, a year earlier. Analysts polled by FactSet expected 41 cents a share. \n\n\n  Revenue climbed to $132.9 million from $3.1 million a year earlier. Analysts expected $119.4 million. The growth was driven by sales of the Yutrepia treatment for pulmonary hypertension. Product sales of Yutrepia were $129.9 million in the quarter, the company said. \n\n\n  The company began shipping Yutrepia to U.S. customers in June, following approval by the Food and Drug Administration on May 23, 2025. \n\n\n \n\n\n  Write to Christopher Kuo at chris.kuo@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 11, 2026 12:36 ET (16:36 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}